Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Article from Phase II study in prostate cancer now published in the March issue of Journal of Nuclear Medicine and highlighted as best clinical investigation article

As previously communicated in December 2020, results from the investigator-initiated phase II study performed by researchers at Rigshospitalet were available in 2020. Now, these results are published in the March 2021 issue of the Journal of Nuclear Medicine, which is the most recognized scientific journal in the field of nuclear medicine (highest impact factor). Furthermore, the article (available here)  has been selected as Featured Clinical Investigation Article of the March issue.The phase II study The phase II study aimed to evaluate the

Change in Number of Shares in Nanologica AB

The number of shares in Nanologica AB (publ) has changed during the month of February as a result of options from the stock option program 2018/21 being exercised.A share-based incentive program of a maximum of 483 883 options was decided by the Annual General Meeting May 31, 2018. The program expires July 1st, 2021 and the options may be exercised any time before that to a strike price of SEK 9.3. According to the Financial Instruments Trading Act (1991:980), any changes in the total number of shares in Swedish publicly traded companies shall be made public per the last day of trade of the

Kamux’s transfer of own shares for payment of share-based incentives 2020

Kamux Corporation    Stock Exchange Release    26 February 2021 at 9:10 (EET) Kamux’s transfer of own shares for payment of share-based incentives 2020 The Board of Directors of Kamux Corporation (“Company”) has confirmed the remuneration to be paid to the key personnel of the Kamux Group in accordance with the terms and conditions of the share-based incentive scheme and the earnings criteria set for the year 2020. According to the terms and conditions of the share-based incentive scheme 2020 and after the deduction of the cash payment portions of the remunerations meant for taxes and

Changes in the roles and responsibilities of the members of Kamux Corporation’s Management Team

Kamux Corporation    Stock Exchange Release    26 February 2021 at 9:10 (EET) Changes in the roles and responsibilities of the members of Kamux Corporation’s Management Team Tommi Iiskonmäki (b. 1977, M.Sc. Econ.) has been appointed as Country Director of Kamux Sweden and he will continue in his new position as Member of the Group Management Team. Earlier he has acted as Country Director of Kamux Finland and Member of the Group Management Team, in addition also as HR Director, and in 2016―2017 as acting Country Director of Kamux Sweden. Ilkka Virtanen (b. 1980, M.Sc. Econ.) has

Otello Announces Definitive Agreement to sell AdColony to Digital Turbine

Otello announced today that it has entered into a definitive agreement to sell AdColony to Digital Turbine, Inc. (Nasdaq: APPS) for a total estimated consideration of $400 million. Digital Turbine is a global mobile technology company, passionate about delivering the right content to the right person at the right time across all Android devices. The company’s on-demand media platform powers frictionless app and content discovery, user acquisition and engagement, operational efficiency, and monetization opportunities. Digital Turbine’s technology platform has been adopted by more than 40

Alligator Bioscience AB: Year-end Report January-December 2020

Continued focus on clinical development. “Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with metastatic cancer. The results show a promising safety profile with only minor drug-related side effects.”  Per Norlén, CEO Alligator Bioscience   SIGNIFICANT EVENTS OCTOBER-DECEMBERMitazalimab:•    New preclinical comparative data showed that mitazalimab has highly competitive immunostimulatory characteristics.•    IND approved for forthcoming clinical studies in the US.•    CTA submitted for launch of the forthcoming Phase II study in

Conversion of shares

According to Essity’s articles of association, owners of Class A shares have the right to have such shares converted to Class B shares. Conversion reduces the total number of votes in the company. When such a conversion has occurred, the company is obligated by law to disclose any such changes in this manner.In February, at the request of shareholders, 600 Class A shares were converted to Class B shares. The total number of votes in the company thereafter amounts to 1,257,952,737. The total number of registered shares in the company amounts to 702,342,489 of which 61,734,472 are Class A

Change in the number of shares and votes in BioInvent International AB

Lund, Sweden, February 26, 2021 – BioInvent International AB (publ) (Nasdaq Stockholm: BINV) today announced that the company’s total number of shares as per February 26, 2021 amounts to 42,210,495 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the directed issue of MSEK 143 to Swedish and international institutional investors by issuance of 2,834,399 shares, announced on February 23, 2021.   About BioInventBioInvent International AB (Nasdaq Stockholm: BINV) is a clinical stage company that discovers and develops novel

Bluestep Bank AB (publ) Year-End Report 2020

The year in brief   Performance and financial position · Lending to the public amounted to SEK 16 116m (SEK 16 150m). Growth was reduced by both the sale of the personal loan portfolio and weakening of the Norwegian krone (NOK). Adjusted for personal loans and currency effects, lending rose by 12%. · New lending for the year increased by 7% to SEK 6 197m (SEK 5 805m). Adjusted for personal loans and currency effects, the increase was 22%. · Full year operating profit amounted to SEK 215m (SEK 275m). The decrease is attributable to one-off costs resulting from restructuring

Electrolux Professional acts for food support and sustainable cooking together with the Electrolux Food Foundation

Electrolux Professional is proud to announce the support of the Electrolux Food Foundation, an independent, non-profit organization that supports initiatives to inspire more sustainable food choices among professionals and consumers, and to support people in need in the communities around us.Since food is a major battleground in the fight against climate change, the foundation’s focus is well aligned with the Electrolux Professional commitment to contribute to change through its Sustainability Commitment, that supports the UN Agenda 2030 and Sustainable Development Goals. Niklas

Year-end report: First commercial installation of TES.POD started in Dubai

Azelio won its first order for TES.POD® in December. The company thus reached a major milestone in the commercialisation of its energy storage system. The order is from ALEC Energy, which will install Azelio’s technology in one of the world’s largest solar parks, the Mohammed Bin Rashid Al Maktoum Solar Complex in Dubai, where it will be part of a mini-grid together with inter alia solar panels and batteries. This will provide renewable energy 24 hours a day, which is an important step in meeting the climate transition. Azelio began installation on site on 20 December. In the fourth

Change in the number of votes in AcadeMedia

The votes in AcadeMedia has changed through conversion of 42,337 C shares to 42,337 ordinary shares. These shares now have one vote per share, totally 42,337 votes.  The conversion follows that all criteria in AcadeMedia’s share-based incentive program, adopted by the Annual General Meeting on November 24, 2017, was met and the qualifying participants have received these ordinary shares. As a result of the conversion, the number of votes has increased with 38,103.3 from 105,324,927.2 to 105,363,030.5. The total number of shares is unchanged. Today, the last trading day of the month,

K-Fast Holding AB: Interim report January–December 2020

Financial ratios for the period 1 January–31 December 2020 +---------------------------------+---------+--------+---------+---------+|  Financial ratios |    2020 |   2019 |   2020 |   2019 || | Oct–Dec |Oct–Dec | Jan–Dec | Jan–Dec |+---------------------------------+---------+--------+---------+---------+|  Rental income, SEK million |  56.2 | 44.7 | 203.9 |  156.8 |+---------------------------------+---------+--------+---------+---------+|  Profit from property |  19.1 | 8.6 | 75.3 |  52.9 |

Tecnotree Corporation Financial Report for Q4 and Full Year 2020 (unaudited)

Tecnotree Corporation Financial Statement Release 26 February 2021 at 09:00 (CET +1)Strong earnings and cash flow Fourth quarter 2020 · Fourth quarter net sales was EUR 14.2 (14.1) million. · The adjusted operating result for the quarter was EUR 4.3 (4.1) million and the operating result 4.3 (4.1) million. · The adjusted result for the quarter was EUR 4.3 (2.8) million and the result EUR 4.3 (2.8) million · The order book at the end of the period stood at EUR 32.1 (25.5) million. · Fourth quarter cash flow after investments was EUR 2.3 (-1.3) million. · Earnings per

Year-end report 2020

Gothenburg, February 26, 2021 - Vicore Pharma Holding AB (publ) publishes the year-end report for 2020.Important events during the fourth quarter · In October, Vicore announced completion of patient enrollment in the phase II study in patients with COVID-19. · In October, Vicore announced the nomination committee for the 2021 Annual General Meeting. · In November, Vicore strengthened its pipeline with the acquisition of novel AT2R (angiotensin II type 2-receptor) agonists and decided on an issue in kind of 142,054 shares. · In November, Vicore announced changes in the

Saga Pure ASA: Prospectus Summary for transfer of listing from Euronext Expand to Oslo Børs

Oslo, Norway, 26 February 2021. Reference is made to the announcement on 24 February 2021 regarding Oslo Børs' resolution to admit the shares of Saga Pura ASA to listing on Oslo Børs. The first day of trading of the Company's shares on Oslo Børs will be on 1 March 2021. Consequently, the last day of trading of the Company's shares on Euronext Expand will be today, 26 February 2021. The ticker and ISIN of the Company's shares will remain unchanged. In connection with the transfer of listing from Euronext Expand to Oslo Børs, Saga Pure ASA hereby publish a prospectus summary, serving

Scout Gaming publishes Q4 2020: Revenues increased 69% to SEKm 16.9, EBITDA improved to SEKm -5.8, positive cashflow from operating activities

“We continue to undergo strong growth, revenues increased by 69% to SEK 16.9 million during the fourth quarter and during the full year 2020, total revenue base amounted to SEK 46.9 million. During the full year, total revenue base thus grew by 84 percent, despite a strong negative impact from COVID-19 at the end of the first and sizable parts of the second quarter - when the global sports calendar was halted. In a longer perspective, COVID-19 has resulted in a faster pace of digitalization in general and for companies operating in the entertainment sector in particular, which has benefited

Frill Holding AB publishes financial report 2020

STOCKHOLM, February 26, 2021 08:00 CET This information is information that Frill Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation.In December 2020, Frill Holding completed the acquisition of Bezzt AB and initiated a strategy that will strengthen the company and the brands associated with it. The acquisition is reported in accordance with the principles for reverse acquisition, where Bezzt is seen as the accounting acquirer and Frill Holding as the acquired party. Following the acquisition, the shareholders in Bezzt AB own 53% of the shares in Frill Holding

Swedbank Robur Sustainable Investments 2020

Swedbank Robur's annual report Sustainable Investments presents how the fund company integrate, support and push sustainability issues through their investments. At the beginning of 2020, Swedbank Robur started the implementation of their climate strategy, and launched six funds defined to be managed in line with the Paris Agreement. Swedbank Robur Råvarufond was also transformed into Transition Energy - and got a new and changed investment focus to encompass companies that contribute to the energy supply of the future. In addition, the fund company’s Policy for Responsible Investments was

ZINZINO AB (PUBL): YEAR-END REPORT 2020

INCREASED SHARE DIVIDEND AFTER RECORD CLOSING OF THE YEAR The fourth quarter of 2020 was the strongest quarter ever in the Company’s history regarding sales. Total revenues in the Group increased by 44% and amounted to SEK 340.4 (236.3) million. This is due to sales growth in all regions. The strongest growth continued to be found in the Central European countries, but Asia and North America also increased significantly during the quarter. Profitability was also very good and the EBITDA result amounted to SEK 37.4 (6.3) million for the quarter. The EBITDA margin amounted to the record

Mycronic receives order for two SLX systems

Mycronic AB (publ) has received an order for two SLX mask writers from an existing customer in the USA. The total order value is between USD 8 and 12 million. Delivery of the first SLX system is scheduled for the fourth quarter of 2021, while delivery of the second system is scheduled for the first half-year of 2022.The SLX laser mask writer was launched in October 2019 to meet rising demand for photomasks for the semiconductor industry, which is driven by long-term trends, and to meet the future need for replacement and modernization. Photomasks made by laser mask writers are very

DanCann Pharma A/S publishes Year-end report for 2020

COPENHAGEN, Denmark, 26 February 2021 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”) today releases its results for the period 1 January – 31 December 2020. The Year-end report is available as an attached document to this press release and on www.dancann.com.Fourth quarter 2021 (1 October – 31 December) · Net sales was KDKK 0 (0) · Operating profit (EBIT) was -2,721 (-493) · Result per share (DKK) was -0.07 (-460,000)* · Equity ratio was 0.89 (-0.42) Full year 2020 (1 January – 31 December) · Net sales was KDKK 0 (0) · Operating profit (EBIT)

There are no items matching the current filter
There are no more items matching the current filter
Back to top